1557 results about "Cell Membrane Proteins" patented technology

The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and / or prevention of diseases caused by immunopathy.

Systems and methods that control the size and composition of emulsified droplets, multi-lamellar and asymmetric vesicles, encapsulation of reagents, membrane proteins, and sorting of vesicles / droplets. More particularly, microfluidic devices for controlled viscous shearing of oil-water emulsions of micro- and nano-scale droplets, the subsequent formation of amphiphilic vesicles such as liposomes, polymer vesicles, micelles, and the like, the post-assembly and post-processing of the droplets including splitting, fusing, sorting and the like, polymer emulsions, and the integration of amphiphilic vesicle production-line on a single microfluidic chip. Preferably, the microfluidic device enables oil-water co-flows with tunable viscous shear forces higher than the immiscible interfacial tension forces that generate favorable conditions for droplet formation.

Compositions are provided that comprise antibody against membrane proteins such as chemokine receptors. In particular, monoclonal human antibodies against human CXCR4 are provided that are capable of inhibiting HIV infection and chemotaxis in human breast cancer cells. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection and cancer, for screening drugs, and for diagnosing diseases or conditions associated with interactions with chemokine receptors.

Particular aspects provide electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions), and therapeutic compositions and methods comprising use thereof in treating at least one symptom of cystic fibrosis. In particular embodiments, at least one symptom of cystic fibrosis treated by the present invention include inhibition of Pseudomonas infection, synergy with tobramycin (including TOBI) for use against bacterial infection, and synergy with a bronchiodilator. In particular embodiments, the electrokinetically-generated fluids or therapeutic compositions and methods comprise combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). In certain aspects, the methods comprise regulating or modulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).

Compounds that can recognize selectively both PD-1 protein and a membrane protein co-existing with PD-1 on a cell membrane, and can transmit a suppressive signal of PD-1. The compounds are useful for medical treatment and / or prevention of diseases caused by immune abnormality.